Media
Press Releases
Please note, all press releases older than a year can be found at https://www.sedarplus.ca/
PharmAla Files Final Base Shelf Prospectus and Signs Term Sheet with Radium Capital
Posted: Nov 03, 2025
CEO Letter To Shareholders
Posted: Oct 31, 2025
PharmAla Launches Nexus Portal for MDMA Prescribers and Therapists
Posted: Oct 08, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to Johns Hopkins
Posted: Oct 02, 2025
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
Posted: Sep 25, 2025
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
Posted: Sep 19, 2025
PharmAla Completes Import of LaNeo MDMA for U.S Distribution
Posted: Sep 08, 2025
PharmAla Incorporates Australian Entity for Clinical Research
Posted: Sep 03, 2025
PharmAla Delivers MDMA to Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License
Posted: Aug 07, 2025
PharmAla Issues Q3 Financial Statements
Posted: Jul 25, 2025
PharmAla Files Preliminary Base Shelf Prospectus
Posted: Jun 19, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to Yale University, Provides Investor Update
Posted: Jun 03, 2025
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
Posted: May 30, 2025
PharmAla Biotech Launches Phenesafe AI Drug Discovery Platform for Novel Phenethylamines
Posted: May 15, 2025
PharmAla Issues Q2 Financial Statements
Posted: Apr 30, 2025
PharmAla Contracts with Partner to Act as US Distributor
Posted: Mar 24, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
Posted: Mar 20, 2025
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
Posted: Mar 10, 2025
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
Posted: Mar 03, 2025
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
Posted: Feb 27, 2025
PharmAla Biotech Annual General Meeting Materials
Posted: Feb 26, 2025
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
Posted: Feb 06, 2025
PharmAla Issues Q1 Financial Statements
Posted: Jan 29, 2025
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
Posted: Jan 20, 2025
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
Posted: Dec 20, 2024
PharmAla Announces Private Placement
Posted: Dec 13, 2024
Search Releases
Type keywords to filter the list of press releases:
Media Inquiries
Nicholas Kadysh, CEO
press@pharmala.ca
PharmAla's Earning & Financial Webinar
A Discussion On: Third Party Insurance for Psychedelic Assisted Therapy
PharmAla Biotech Investors Webinar
MDMA: Real World Efficacy Explored
FDA: Guidance | A Discussion On Psychedelic Regulations Globally
Optimizing Clinical Trial Design and The State of the Market
'Cortexa' explained. A Discussion on PharmAla Biotech and Vitura Health Limited Recent JV
Psychedelics Today: Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
The Dales Report - Pharmala Stock Succeeds Through Tough Markets
Changes Announced By The TGA & What It Means For Psychedelics Webinar
PharmAla Biotech | Planning Psychedelic Trials & Navigating the Import/Export Process Webinar
PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia
PharmAla Biotech signs supply deal with Global Wellness Strategies to provide MDMA for trial
Psychedelics 101 | February 8, 2022
Rick Doblin, Exec. Director, MAPS & Nick Kadysh, President & CEO, PharmAla Biotech | MDMA Conference